BioCryst Pharmaceuticals Inc (BCRX) — Capital Reinvestment Ratio
Latest as of December 2025:
0.00x
BioCryst Pharmaceuticals Inc (BCRX) has a Capital Reinvestment Ratio of 0.00x as of December 2025, meaning it reinvests 0% of its operating cash flow ($276.04 Million) in capital expenditures ($802.00K). See BioCryst Pharmaceuticals Inc (BCRX) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
$276.04 Million
USD
Capital Expenditures
$802.00K
USD
Data as of
Dec 2025
Most recent filing
BioCryst Pharmaceuticals Inc Capital Reinvestment Ratio (2025–2025)
This chart tracks BioCryst Pharmaceuticals Inc's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for BioCryst Pharmaceuticals Inc (2025–2025)
Year-by-year Capital Reinvestment Ratio for BioCryst Pharmaceuticals Inc from 2025 to 2025. For live market cap and broader valuation context, see BCRX market cap.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.01x | $329.88 Million | $2.47 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow